Abdel Abu Shamat, MD
Nephrology · Lake Charles, LANPI 1528053824
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 94.8% of the total across 267 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 25 manufacturers, the largest accounting for just 16.1% — the pattern of someone who eats at a lot of different presentations. Reporting peaked in 2022 at $1,403 and has fallen 70.6% since, to $413 in 2025.
Across 267 payments — averaging $21.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$930
- Amgen$635
- Akebia Therapeutics Inc$565
- Mallinckrodt Hospital Products Inc.$493
- ANI Pharmaceuticals, Inc.$446
- Fresenius USA Marketing, Inc.$401
- plus $2K from 19 others
What the payments were for
- Food & beverage$5,47095%
- Education$3035%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 43 | $930 |
| Amgen(2 entities) | 26 | $635 |
| Akebia Therapeutics Inc | 31 | $565 |
| Mallinckrodt Hospital Products Inc. | 19 | $493 |
| ANI Pharmaceuticals, Inc. | 19 | $446 |
| Fresenius USA Marketing, Inc. | 19 | $401 |
| Otsuka America Pharmaceutical, Inc. | 19 | $385 |
| Vifor Pharma, Inc. | 21 | $383 |
| Bayer | 14 | $312 |
| Daiichi Sankyo Inc. | 12 | $195 |
| Nxstage Medical, Inc. | 2 | $177 |
| Calliditas Therapeutics US Inc. | 6 | $145 |
| GSK | 7 | $122 |
| Novartis | 5 | $100 |
| Kyowa Kirin, Inc. | 4 | $90 |
| Aurinia Pharma U.S., Inc. | 4 | $74 |
| Pharmacosmos Therapeutics Inc. | 3 | $68 |
| Mallinckrodt Enterprises LLC | 4 | $60 |
| Boehringer Ingelheim | 3 | $58 |
| Ascendis Pharma Endocrinology Inc | 1 | $26 |
| Novo Nordisk | 1 | $25 |
| Xeris Pharmaceuticals, Inc. | 1 | $23 |
| Lilly USA, LLC | 1 | $22 |
| Ultragenyx Pharmaceutical Inc. | 1 | $18 |
| Travere Therapeutics, Inc. | 1 | $18 |
How this compares
$5,772 in reported general payments places this provider in the 75th percentile of 206 nephrology providers in Louisiana.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| TarpeyoBudesonide | 23 | $386,397 |
| FarxigaDapagliflozin Propanediol | 73 | $57,269 |
| VelphoroSucroferric Oxyhydroxide | 12 | $33,744 |
| VeltassaPatiromer Calcium Sorbitex | 25 | $22,003 |
| AuryxiaFerric Citrate | 13 | $19,411 |
| JardianceEmpagliflozin | 26 | $16,221 |
| Sevelamer Carbonate | 83 | $7,864 |
| Calcium Acetate | 40 | $4,070 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 17 | $2,903 |
| Nifedipine ErNifedipine | 70 | $1,977 |
| Losartan Potassium | 222 | $1,918 |
| Febuxostat | 15 | $1,673 |
| Labetalol Hcl | 44 | $1,543 |
| Hydralazine Hcl | 156 | $1,479 |
| Potassium Chloride | 64 | $1,376 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Calliditas Therapeutics US Inc.Tarpeyo | $145 | $386,39723 claims |
| AstraZenecaFarxiga | $930 | $57,26973 claims |
| Fresenius USA Marketing, Inc.Velphoro | $401 | $33,74412 claims |
| Akebia Therapeutics IncAuryxia | $565 | $19,41113 claims |
| Boehringer IngelheimJardiance | $58 | $16,22126 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 206 nephrology providers in Louisiana.
Other nephrology in Lake Charles
- Ahad LodhiLake Charles$6K
- Sreedhara AllaShreveport$722K
- Anthony BlalockLafayette$350K
- Juan Carlos VelezNew Orleans$282K
- Jones SamuelBaton Rouge$207K
- Jon MaresCovington$103K
- Raja ZabanehShreveport$57K
- Michael TouchyNew Orleans$56K
- Kenneth AbreoShreveport$42K
- Michael LiuOpelousas$36K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.